Photo: markets.businessinsider.com
Regeneron Reports Q3 2025 Growth Amid Strong Dupixent Sales and FDA Approval
Regeneron Pharmaceuticals reported a 1% revenue increase in Q3 2025, driven by strong sales of Dupilumab and FDA approval of Cemiplimab, highlighting its growth trajectory.
- Regeneron Pharmaceuticals Q3 2025 revenues reached $3.75 billion, reflecting a 1% increase compared to Q3 2024 amid strategic product performance.
- Global net sales of Dupilumab surged 27% to $4.86 billion, showcasing its strong market demand and positioning within Regeneron Pharmaceuticals portfolio.
- The FDA approved Cemiplimab as the first and only immunotherapy for high-risk adjuvant treatment, marking a significant milestone for Regeneron Pharmaceuticals in oncology.
Por Qué Es Relevante
This growth signals Regeneron Pharmaceuticals resilience and innovation in a competitive market, particularly with Dupilumabs performance. The FDAs approval of Cemiplimab also positions the company favorably for future oncology advancements.